Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.
Seventy percent of liver cancer patients had either a partial response or stable disease.
Checkpoint inhibitor alone or in combination shows benefits for different types of colorectal cancer.
People who received preoperative gemcitabine and Teysuno lived 10 months longer.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Keytruda improved survival in people with favorable tumor biomarkers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.